Crossmark

Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in Chile

Crossref DOI link: https://doi.org/10.1016/j.gastre.2022.07.004

Published Print: 2022-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Reyes, Diego

Ortiz, Javier

Fuentes-López, Eduardo

Budnik, Sigall

Gándara, Vicente

Gallardo, Andrea

Seydewitz, María Francisca

Candia, Roberto

Vargas, José Ignacio

Rollan, María Paz

Godoy, Javiera

Rollan, Antonio

Mansilla, Rodrigo

Arenas, Alex

Chahuán, Javier

Espino, Alberto

Pizarro, Margarita

Riquelme, Arnoldo
Funding

Funding for this research was provided by:

Horizon 2020 Framework Programme

European Commission
License Information

Text and Data Mining valid from 2022-08-01

stm-asf valid from 2022-08-01

stm-asf valid from 2022-08-01

stm-asf valid from 2022-08-01

stm-asf valid from 2022-08-01

stm-asf valid from 2022-08-01
More Information

This article is maintained by: Elsevier

Article Title: Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in Chile

Journal Title: Gastroenterología y Hepatología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastre.2022.07.004

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.gastrohep.2021.11.010

Content Type: article

Copyright: © 2021 Elsevier España, S.L.U. All rights reserved.